Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 23, 2019 08:30 ET | Source: Atossa Genetics Inc.

Atossa Genetics to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference

SEATTLE, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
October 16, 2019 08:30 ET | Source: Atossa Genetics Inc.

Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology

SEATTLE and ENCINO, Calif., Oct. 16, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for...
September 30, 2019 08:30 ET | Source: Atossa Genetics Inc.

Atossa Genetics Announces Preliminary Results from Phase 1 Study of Modified-Release Tablet Oral Endoxifen

SEATTLE, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
September 06, 2019 08:30 ET | Source: Atossa Genetics Inc.

Atossa Genetics to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference

SEATTLE, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
September 03, 2019 08:00 ET | Source: Atossa Genetics Inc.

Atossa Genetics Announces Completion of Enrollment and Dosing in Phase 1 Clinical Trial of New Proprietary Modified-Release Oral Endoxifen Tablet

SEATTLE, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
August 13, 2019 13:26 ET | Source: Atossa Genetics Inc.

Atossa Genetics Announces Second Quarter 2019 Financial Results and Provides Company Update

SEATTLE, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer...
July 30, 2019 08:30 ET | Source: Atossa Genetics Inc.

Atossa Genetics CEO Steven Quay Gives Tedx Talk At University of Washington Regarding the the Relationship of Dense Breast Tissue and Breast Cancer Risk

SEATTLE, July 30, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
July 17, 2019 08:30 ET | Source: Atossa Genetics Inc.

Atossa Genetics Provides Information on FDA Expanded Access Policy and Requests

SEATTLE, July 17, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
July 11, 2019 08:30 ET | Source: Atossa Genetics Inc.

Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Phase 1 Clinical Trial Initiated

SEATTLE, July 11, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
June 27, 2019 08:00 ET | Source: Atossa Genetics Inc.

Atossa Genetics’ Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density

SEATTLE, June 27, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...

keyboard_arrow_left Previous Page